ClinicalTrials.gg
CompletedNCT00430729Updated Nov 30, 2016

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)

A Phase 3 interventional study of Roflumilast in Chronic Obstructive Pulmonary Disease and COPD, sponsored by AstraZeneca. Completed at 14 sites in 14 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-11-30.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,100
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Roflumilast · Pulmonary Disease, Chronic Obstructive.

Enrollment
6th of 32
1,100 · median 154
Started
2003
with 2 others
Phase 3
16 of 32
none open now
Registered
11th of 32
by date
Lead sponsor
18 of 32
AstraZeneca

Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, this one is the 6th largest by enrollment, is one of 3 that started in 2003, is one of 16 in phase 3, and was the 11th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive is open now. Recruiting first, the newest first:

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effect of 500mcg roflumilast vs placebo on exacerbation rate and pulmonary function as well as quality of life in patients with chronic obstructive pulmonary disease (COPD).

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
  • COPD

Keywords

  • Roflumilast
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • /FVC ratio (post-bronchodilator) ≤70%
  • FEV1 (post-bronchodilator) ≤50% of predicted
  • Current smoker or ex-smoker
  • Clinically stable indicated by no exacerbation and no change in COPD treatment of within 4 weeks prior to baseline
  • Availability of a chest x-ray dated a maximum of 6 months prior to study baseline visit B0 or a willingness to have a chest x-ray performed before baseline

Main Exclusion Criteria:

  • COPD exacerbation indicated by a treatment with systemic not stopped 4 weeks prior to baseline
  • Lower respiratory tract infection not resolved 4 weeks prior to baseline
  • Diagnosis of asthma and/or other relevant lung disease
  • Known alpha-1-antitrypsin deficiency
  • Need for long-term oxygen therapy defined as ≥16 hours/day
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
1,100 participants

Interventions

06

What researchers measure

Primary outcomes

  1. The frequency of patients experiencing at least one moderate or severe exacerbation during the treatment period.

  2. Change in FEV1 from baseline during the treatment period.

Secondary outcomes

  1. Pulmonary function variables; quality of life variables;patient diary variables;safety

07

Study locations

14 sites
  • ALTANA Pharma
    Cities in Australia, Australia
  • ALTANA Pharma
    Cities in Austria, Austria
  • ALTANA Pharma
    Cities in Canada, Canada
  • ALTANA Pharma
    Cities in France, France
  • ALTANA Pharma
    Cities in Hungary, Hungary
  • ALTANA Pharma
    Cities in Italy, Italy
  • ALTANA Pharma
    Cities in the Netherlands, Netherlands
  • ALTANA Pharma
    Cities in Poland, Poland
  • ALTANA Pharma
    Cities in Portugal, Portugal
  • ALTANA Pharma
    Cities in the Russian Federation, Russian Federation
  • ALTANA Pharma
    Cities in South Africa, South Africa
  • ALTANA Pharma
    Cities in Spain, Spain
  • ALTANA Pharma
    Cities in Switzerland, Switzerland
  • ALTANA Pharma
    Cities in the United Kingdom, United Kingdom
08

References and documents

Publications

  • Facius A, Krause A, Claret L, Bruno R, Lahu G. Modeling and Simulation of Pivotal Clinical Trials Using Linked Models for Multiple Endpoints in Chronic Obstructive Pulmonary Disease With Roflumilast. J Clin Pharmacol. 2017 Aug;57(8):1042-1052. doi: 10.1002/jcph.885. Epub 2017 Apr 17. PubMed 28419462 ↗
  • Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. Respir Res. 2011 Jan 27;12(1):18. doi: 10.1186/1465-9921-12-18. PubMed 21272339 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00430729
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 2, 2007
Start date
Jan 2003
Last update
Nov 30, 2016

Study contacts

AstraZeneca AstraZeneca
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion